Overview

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Status:
RECRUITING

Trial end date:
2032-08-31

Target enrollment:

Participant gender:

Summary

This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

Phase:

PHASE1

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

Poseida Therapeutics, Inc., a member of the Roche Group

Treatments:

Cyclophosphamide
fludarabine